IRAK1 and myeloid sarcoma: Interestingly, SPMS was more prevalent than RRMS in MS patients carrying the AC + CC genotypes of IRAK-1 rs3027898 (AC + CC vs. AA, adjusted OR (95% CI) = 3.31 (1.24–8.84), P = 0.012) or the AA genotype of miR-155 rs767649 (AA vs. TT + AT, adjusted OR (95% CI) = 4.53 (1.41–14.51), P = 0.01).